Primary results from a phase 2a study of zanidatamab (zani) plus palbociclib (palbo) plus fulvestrant (fulv) in HER2+/HR+ metastatic breast cancer (mBC)

被引：1
|
作者：
Escriva-de-Romani, Santiago
Cejalvo, Juan Miguel
Alba, Emilio
Friedmann, Jennifer
Lescure, Alvaro Rodriguez
Savard, Marie-France
Pezo, Rossanna C.
Gion, Maria
-Borrego, Manuel Ruiz
Hamilton, Erika
Pluard, Timothy
Webster, Marc
Beeram, Muralidhar
Linden, Hannah
Saura, Cristina
Shpektor, Diana
Salim, Bob
Harvey, Phoebe
Hurvitz, Sara
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-LBO1-04
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBO1-04
引用
收藏
页数：5
相关论文
共 50 条
  • [31] A phase I trial of palbociclib (palbo) and bosutinib (bos) with fulvestrant (fulv) in patients (pts) with hormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) refractory to an aromatase inhibitor (AI) and a CDK4/6 inhibitor (CDK4/6i)
    Mainor, Candace Bavette
    Barrows, Elizabeth Dominic
    Wang, Hongkun
    Lynce, Filipa
    Ashai, Nadia
    Collins, Julie Marie
    Swanson, Nicole
    Castle, Julie
    Novielli, Antonella
    Slingerland, Joyce
    Isaacs, Claudine
    Pohlmann, Paula R.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [32] postMONARCH: A phase 3 study of abemaciclib plus fulvestrant versus placebo plus fulvestrant in patients with HR+, HER2-, metastatic breast cancer following progression on a CDK4 & 6 inhibitor and endocrine therapy
    Kalinsky, Kevin
    Layman, Rachel M.
    Kaufman, Peter A.
    Graff, Stephanie L.
    Bianchini, Giampaolo
    Martin, Miguel
    Zhou, Yanhong
    Knoderer, Holly
    Litchfield, Lacey
    Andrew Wander, Seth
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [33] Genomic analysis of circulating tumor DNA (ctDNA) from patients with HR+, HER2-mutant metastatic breast cancer (MBC) enrolled in SUMMIT: mechanisms of acquired resistance to neratinib plus fulvestrant plus trastuzumab (N plus F plus T)
    Ma, Cynthia
    Waisman, James
    Brufsky, Adam M.
    Yang, Eddy S.
    Wildiers, Hans
    Crown, John P.
    Piha-Paul, Sarina A.
    Suga, Jennifer M.
    Garcia-Saenz, Jose Angel
    Gambardella, Valentina
    Guerrero, Angel
    Stemmer, Salomon
    Bose, Ron
    Novara-Demgen, Tonya
    DiPrimeo, Daniel
    Eli, Lisa D.
    Jhaveri, Komal
    CANCER RESEARCH, 2023, 83 (05)
  • [34] Monarch 2: Interim Overall Survival of Abemaciclib Plus Fulvestrant in Patients with HR+, HER2-Advanced Breast Cancer
    Grischke, Eva Maria
    Sledge, George W.
    Toi, Masakazu
    Neven, Patrick
    Sohn, Joo Hyuk
    Inoue, Kenichi
    Pivot, Xavier
    Burdaeva, Olga
    Masuda, Norikazu
    Kaufman, Peter
    Koh, Han
    Conte, Pierfranco
    Barriga, Susana
    Hurt, Karla
    Frenzel, Martin
    Johnston, Stephen
    Llombart-Cussac, Antonio
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 15 - 15
  • [35] Palbociclib plus fulvestrant as second- or later-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2-breast cancer in Germany: Interim results of the INGE-B phase II study
    Lueftner, D.
    Welslau, M. K.
    Liersch, R.
    Deryal, M.
    Brucker, C.
    Rauh, J.
    Welt, A.
    Zaiss, M.
    Sahlmann, J.
    Houet, L.
    Vannier, C.
    Potthoff, K.
    Marschner, N. W.
    ANNALS OF ONCOLOGY, 2019, 30
  • [36] Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2-Advanced Breast Cancer
    Fasching, Peter A.
    Delea, Thomas E.
    Lu, Yen-Shen
    De Boer, Richard
    Hurvitz, Sara A.
    Moynahan, Aaron
    Chandiwana, David
    Lanoue, Brad
    Hu, Huilin
    Thuerigen, Astrid
    O'Shaughnessy, Joyce
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 8179 - 8189
  • [37] Palbociclib plus exemestane with GnRH agonist vs capecitabine in premenopausal patients with HR+/HER2-metastatic breast cancer: Updated survival results of the randomized phase 2 study Young-PEARL.
    Park, Yeon Hee
    Lee, Kyung-Hun
    Kim, Gun Min
    Kang, Seok Yun
    Lee, Keun Seok
    Kim, Jee Hyun
    Lee, Kyoung Eun
    Ahn, Hee Kyung
    Lee, Moon Hee
    Kim, Hee Jun
    Kim, Hanjo
    Koh, Su-Jin
    Kim, Ji-Yeon
    Sohn, Joohyuk
    Kim, Sung-Bae
    Ahn, Jin Seok
    Kim, Seonwoo
    Cho, Hyun
    Jung, Kyung Hae
    Im, Seock-Ah
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA1002 - LBA1002
  • [38] Efficacy and activity of treatments after progression from palbociclib plus endocrine therapy in patients with HR+/HER2- metastatic breast cancer: a prospective, monocentric study
    Palumbo, Raffaella
    Quaquarini, Erica
    Saltalamacchia, Giuseppe
    Malovini, Alberto
    Lapidari, Pietro
    Tagliaferri, Barbara
    Mollica, Ludovica
    Teragni, Cristina Maria
    Barletta, Chiara
    Locati, Laura Deborah
    Sottotetti, Federico
    DRUGS IN CONTEXT, 2024, 13
  • [39] Proxalutamide plus Endocrine Therapies in Women with HR+/HER2-/AR+ Metastatic Breast Cancer: A Phase Ic Study
    Li, Hui-Ping
    Song, Guohong
    Jiang, Hanfang
    Liang, Xu
    Wang, Xiaojia
    Yang, Hua
    Zhang, Lili
    Tong, Youzhi
    CANCER RESEARCH, 2024, 84 (09)
  • [40] Abemaciclib plus fulvestrant in East Asian women with HR+, HER2-advanced breast cancer: Overall survival from MONARCH 2
    Huang, C-S.
    Toi, M.
    Im, Y-H.
    Iwata, H.
    Sohn, J.
    Wang, H-C.
    Masuda, N.
    Im, S-A.
    Lu, Y.
    Haddad, N.
    Sakaguchi, S.
    Hurt, K.
    Neven, P.
    Llombart-Cussac, A.
    Sledge, G.
    ANNALS OF ONCOLOGY, 2020, 31 : S1258 - S1259
12345